Preeclampsia and aspirin.

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal-Fetal Medicine

Background:

• Preeclampsia (PE) is a major cause of maternal and perinatal mortality.
• Delivery is the only definitive treatment for PE, often resulting in premature birth and increased neonatal complications.
• Aspirin, a non-steroidal anti-inflammatory drug, inhibits prostaglandin and thromboxane synthesis.

Purpose of the Study:

• To review and summarize existing evidence on the efficacy of aspirin for preeclampsia prevention.
• To address the ongoing debate regarding optimal aspirin dosage and timing for prophylactic use in pregnancy.
• To evaluate recent studies investigating higher aspirin doses (150 mg) for PE prevention.

Main Methods:

• Review of published literature and clinical studies on aspirin's role in preeclampsia.
• Analysis of evidence regarding aspirin's mechanism of action, including its effects on prostaglandin and thromboxane A2.
• Examination of data from studies using varying aspirin dosages and treatment initiation times.

Main Results:

• Despite controversial early findings, aspirin is generally accepted as a preventive strategy for PE in clinical practice.
• Accumulating evidence supports aspirin's effectiveness in reducing PE incidence.
• Recent research explores higher aspirin doses, though optimal regimens remain under discussion.

Conclusions:

• Aspirin represents a viable prophylactic measure against preeclampsia.
• Further research and guideline harmonization are needed to define optimal aspirin therapy protocols for PE prevention during pregnancy.
• The use of aspirin in pregnancy requires careful consideration of dosage and timing.